See More

See their struggle

See their struggle

Despite C5i treatment, many patients face ongoing challenges in everyday life1–4

No more than 15%

Retrospective studies of C5i-treated patients have found that:

79% experienced ongoing fatigue
36% required transfusions
93% reported limitations

*15% of patients achieved a ‘major’ or ‘complete’ response, defined as normal-like Hb levels (≥120 g/L in women, ≥130 g/L in men) without requiring transfusions.1
C5i=complement 5 inhibitor; Hb=haemoglobin; MOA=mechanism of action.

References: 1. Risitano AM and de Latour RP. How we(‘ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. BJH. 2021; doi: 10.1111/bjh.17753. 2. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251-263. 3. McKinley CE, Richards SJ, Munir T, et al. Extravascular hemolysis due to C3-Loading in patients with PNH treated with eculizumab: Defining the clinical syndrome. Blood. 2017;130(Supplement 1):3471. 4. Dingli D, Matos JE, Lebrhaunt K, et al. Work productivity loss and quality of life in paroxysmal nocturnal hemoglobinuria among patients receiving C5 inhibitors in the United States. 2020;136(Supplement 1):3.